Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease

Nature Communications
2016.0

Abstract

<jats:title>Abstract</jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by integrating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across the human splanchnic vascular bed, within a genome-scale model of human metabolism. We show that an increased amount of liver fat induces mitochondrial metabolism, lipolysis, glyceroneogenesis and a switch from lactate to glycerol as substrate for gluconeogenesis, indicating an intricate balance of exacerbated opposite metabolic processes in glycemic regulation. These changes were associated with reduced metabolic adaptability on a network level in the sense that liver fat accumulation puts increasing demands on the liver to adaptively regulate metabolic responses to maintain basic liver functions. We propose that failure to meet excessive metabolic challenges coupled with reduced metabolic adaptability may lead to a vicious pathogenic cycle leading to the co-morbidities of NAFLD.

Knowledge Graph

Similar Paper

Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
Nature Communications 2016.0
Integration of Transcriptomics and Lipidomics Profiling to Reveal the Therapeutic Mechanism Underlying Ramulus mori (Sangzhi) Alkaloids for the Treatment of Liver Lipid Metabolic Disturbance in High-Fat-Diet/Streptozotocin-Induced Diabetic Mice
Nutrients 2023.0
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
European Journal of Medicinal Chemistry 2020.0
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Journal of Medicinal Chemistry 2020.0
Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis
Phytomedicine 2023.0
Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease
Clinical Gastroenterology and Hepatology 2013.0
Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice
Antioxidants 2022.0
Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease
Pharmacological Research 2021.0
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis
Drug Discovery Today 2023.0
Synthesis and Biological Evaluation of 5-Benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione Derivatives for the Treatment of Obesity-Related Nonalcoholic Fatty Liver Disease
Journal of Medicinal Chemistry 2012.0